Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, April 22, 2016

Tysabri No Help in SPMS - Drug didn't reduce disability progression but may benefit upper limb function

                                                                  

Click here to receive MS news via e-mail       




VANCOUVER -- Natalizumab (Tysabri) didn't slow disability progression in patients with secondary progressive multiple sclerosis (SPMS), researchers reported here.


The ASCEND trial missed its primary endpoint of reducing progression as measured by a composite endpoint assessing disability unrelated to relapses, Deborah Steiner, MD, of Biogen, reported during the emerging science session at the American Academy of Neurology meeting here.

But Steiner noted that there was a significant benefit on upper extremity function.

"There's a striking contrast between the lack of effect on ambulatory function as measured by the timed 25-foot walk test, and the effects on upper extremity function as measured by the 9-hole peg test," she said.

There are currently no approved therapies for primary progressive or secondary progressive MS -- although data reported here on ocrelizumab, an investigational B-cell targeting therapy by Roche/Genentech, suggested the drug has some efficacy in primary progressive disease.

Click here to continue reading


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information 
.===================================

No comments: